An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Chronic kidney disease is a common complication for people ... The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set ...
Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...
A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease.
Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...
The FDA's decision means Ozempic can now be used to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in patients with both chronic kidney disease ...
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.